Tim M. J. Ewoldt

547 total citations
20 papers, 355 citations indexed

About

Tim M. J. Ewoldt is a scholar working on Pharmacology, Epidemiology and Molecular Medicine. According to data from OpenAlex, Tim M. J. Ewoldt has authored 20 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pharmacology, 15 papers in Epidemiology and 6 papers in Molecular Medicine. Recurrent topics in Tim M. J. Ewoldt's work include Antibiotics Pharmacokinetics and Efficacy (18 papers), Pneumonia and Respiratory Infections (11 papers) and Antibiotic Resistance in Bacteria (6 papers). Tim M. J. Ewoldt is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (18 papers), Pneumonia and Respiratory Infections (11 papers) and Antibiotic Resistance in Bacteria (6 papers). Tim M. J. Ewoldt collaborates with scholars based in Netherlands, Switzerland and Australia. Tim M. J. Ewoldt's co-authors include Alan Abdulla, Birgit C. P. Koch, Henrik Endeman, Anouk E. Muller, Nicole Hunfeld, Diederik Gommers, Teun van Gelder, Soma Bahmany, Brenda C. M. de Winter and Wim J. R. Rietdijk and has published in prestigious journals such as Intensive Care Medicine, Journal of Antimicrobial Chemotherapy and Critical Care.

In The Last Decade

Tim M. J. Ewoldt

20 papers receiving 352 citations

Peers

Countries citing papers authored by Tim M. J. Ewoldt

Since Specialization

Citations

This map shows the geographic impact of Tim M. J. Ewoldt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim M. J. Ewoldt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim M. J. Ewoldt more than expected).

Fields of papers citing papers by Tim M. J. Ewoldt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim M. J. Ewoldt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim M. J. Ewoldt. The network helps show where Tim M. J. Ewoldt may publish in the future.

Co-authorship network of co-authors of Tim M. J. Ewoldt

This figure shows the co-authorship network connecting the top 25 collaborators of Tim M. J. Ewoldt. A scholar is included among the top collaborators of Tim M. J. Ewoldt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim M. J. Ewoldt. Tim M. J. Ewoldt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Target attainment of beta-lactam antibiotics and ciprofloxacin in critically ill patients and its association with 28-day mortality 2024 ·Journal of Critical Care ·Sarah Dräger, Tim M. J. Ewoldt, Alan Abdulla, Wim J. R. Rietdijk, Nelianne J. Verkaik, Peter Van de Vliet, Ilse M. Purmer, Michael Osthoff, Birgit C. P. Koch, Henrik Endeman	2
2	Exploring the Impact of Model-Informed Precision Dosing on Procalcitonin Concentrations in Critically Ill Patients: A Secondary Analysis of the DOLPHIN Trial 2024 ·Pharmaceutics ·Sarah Dräger, Tim M. J. Ewoldt, Alan Abdulla, Wim J. R. Rietdijk, Nelianne J. Verkaik, Christian Ramakers, Evelien de Jong, Michael Osthoff, Birgit C. P. Koch, Henrik Endeman	1
3	Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It? 2023 ·Antibiotics ·(unknown), (unknown), Tim M. J. Ewoldt, Alan Abdulla, Nicole Hunfeld, Anouk E. Muller, Brenda C. M. de Winter, Henrik Endeman, Birgit C. P. Koch	10
4	Predicting Beta-Lactam Target Non-Attainment in ICU Patients at Treatment Initiation: Development and External Validation of Three Novel (Machine Learning) Models 2023 ·Antibiotics ·(unknown), Tim M. J. Ewoldt, (unknown), Matthias Gijsen, Nestor Parolya, (unknown), Isabel Spriet, Henrik Endeman, Jasper J. Haringman, Reinier M. van Hest, Birgit C. P. Koch, Alan Abdulla	4
5	Which patients benefit from model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin at the ICU? 2023 ·International Journal of Antimicrobial Agents ·Tim M. J. Ewoldt, Alan Abdulla, Wim J. R. Rietdijk, Nicole Hunfeld, Anouk E. Muller, Henrik Endeman, Birgit C. P. Koch	5
6	Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: Does inflammation play a role? 2023 ·Journal of Critical Care ·(unknown), (unknown), Nicole Hunfeld, (unknown), Tim M. J. Ewoldt, Sjoerd A.A. van den Berg, Birgit C. P. Koch, Henrik Endeman	1
7	Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions? 2023 ·Journal of Antimicrobial Chemotherapy ·Tim M. J. Ewoldt, Soma Bahmany, Alan Abdulla, Anouk E. Muller, Henrik Endeman, Birgit C. P. Koch	6
8	Stability of 10 Beta-Lactam Antibiotics in Human Plasma at Different Storage Conditions 2023 ·Therapeutic Drug Monitoring ·Soma Bahmany, Tim M. J. Ewoldt, Alan Abdulla, Birgit C. P. Koch	13
9	Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients 2022 ·Clinical Pharmacokinetics ·Tingjie Guo, Alan Abdulla, Birgit C. P. Koch, J. G. Coen van Hasselt, Henrik Endeman, Jeroen Schouten, Paul Elbers, Roger J. M. Brüggemann, Reinier M. van Hest, (unknown), Luca F. Roggeveen, Lucas M. Fleuren, Nicole Hunfeld, Tim M. J. Ewoldt, Anouk E. Muller, Annemieke Dijkstra, Dylan W. de Lange, (unknown), Peter Pickkers, Jaap ten Oever	4
10	High-throughput analysis for the simultaneous quantification of nine beta-lactam antibiotics in human plasma by UPC2-MS/MS: Method development, validation, and clinical application 2022 ·Journal of Pharmaceutical and Biomedical Analysis ·Soma Bahmany, Alan Abdulla, Tim M. J. Ewoldt, (unknown), Brenda C. M. de Winter, Birgit C. P. Koch	7
11	Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients:Current Practice and Future Perspectives With a Focus on Clinical Outcome 2022 ·EUR Research Repository (Erasmus University Rotterdam) ·Birgit C. P. Koch, Anouk E. Muller, Nicole Hunfeld, Brenda C. M. de Winter, Tim M. J. Ewoldt, Alan Abdulla, Henrik Endeman	31
12	Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial 2022 ·Intensive Care Medicine ·Tim M. J. Ewoldt, Alan Abdulla, Wim J. R. Rietdijk, Anouk E. Muller, Brenda C. M. de Winter, Nicole Hunfeld, Ilse M. Purmer, Peter Van de Vliet, Evert‐Jan Wils, Jasper J. Haringman, Annelies Draisma, Tom A. Rijpstra, Attila Karakus, Diederik Gommers, Henrik Endeman, Birgit C. P. Koch	60
13	Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome. 2022 ·Therapeutic Drug Monitoring ·Birgit C. P. Koch, Anouk E. Muller, (unknown), Brenda C. M. de Winter, Tim M. J. Ewoldt, Alan Abdulla, Henrik Endeman	12
14	Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional study 2022 ·BMC Infectious Diseases ·Tim M. J. Ewoldt, Alan Abdulla, (unknown), Nicole Hunfeld, Soma Bahmany, Anouk E. Muller, Diederik Gommers, Suzanne Polinder, Henrik Endeman, Inge Spronk, Birgit C. P. Koch	8
15	The impact of sepsis on hepatic drug metabolism in critically ill patients: a narrative review 2022 ·Expert Opinion on Drug Metabolism & Toxicology ·Tim M. J. Ewoldt, Alan Abdulla, Nicole Hunfeld, (unknown), (unknown), Diederik Gommers, Birgit C. P. Koch, Henrik Endeman	4
16	A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients 2021 ·Expert Opinion on Drug Metabolism & Toxicology ·Alan Abdulla, Tim M. J. Ewoldt, Ilse M. Purmer, Anouk E. Muller, Diederik Gommers, Henrik Endeman, Birgit C. P. Koch	21
17	Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome 2021 ·Therapeutic Drug Monitoring ·Birgit C. P. Koch, Anouk E. Muller, Nicole Hunfeld, Brenda C. M. de Winter, Tim M. J. Ewoldt, Alan Abdulla, Henrik Endeman	10
18	Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT) 2020 ·Critical Care ·Alan Abdulla, Annemieke Dijkstra, Nicole Hunfeld, Henrik Endeman, Soma Bahmany, Tim M. J. Ewoldt, Anouk E. Muller, Teun van Gelder, Diederik Gommers, Birgit C. P. Koch	90
19	The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial 2020 ·BMC Infectious Diseases ·Alan Abdulla, Tim M. J. Ewoldt, Nicole Hunfeld, Anouk E. Muller, Wim J. R. Rietdijk, Suzanne Polinder, Teun van Gelder, Henrik Endeman, Birgit C. P. Koch	65
20	Reduction of Nocturia in Patients Treated with C-PAP for Obstructive Sleep Apnea Syndrome 2016 ·Neurourology and Urodynamics ·Mohammad Sajjad Rahnama’i, (unknown), Tim M. J. Ewoldt, Tom Marcelissen, Michiel H. M. Gronenschild, Peter de Vries	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact